Monthly Return of Equity Issuer on Movements in Securities for the Month ended September 30, 2026
Filed with HKEX · Stock code 2197 · · 11 pages · English
Summary by 6ix AI
The report includes information on authorized and registered share capital, as well as movements in issued shares and treasury shares. It confirms compliance with public float requirements and provides details on share options and other movements in shares. The filing serves to inform the Hong Kong Exchanges and Clearing Limited about the company's securities activities during the specified month.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Clover Biopharmaceuticals Ltd. on 6ix
Earlier from Clover Biopharmaceuticals
- 2026 Interim Report
- Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults
- Clover Announces Additional Positive U.S. Phase I Clinical Data for RSV Re-Vaccination in Older Adults
- Clover Initiates Phase 2 Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
- Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
Follow Clover Biopharmaceuticals into a list and get an email when it puts out news.
Follow Clover Biopharmaceuticals